{
  "meta": {
    "title": "Drugs_Affecting_Cells_Of_Blood",
    "url": "https://brainandscalpel.vercel.app/drugs-affecting-cells-of-blood-baccacd7.html",
    "scrapedAt": "2025-11-29T18:34:04.076Z"
  },
  "questions": [
    {
      "id": 8171,
      "choices": [
        {
          "id": 32652,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isoniazid</span></span></span></p>"
        },
        {
          "id": 32653,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
        },
        {
          "id": 32654,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbamazepine</span></span></span></p>"
        },
        {
          "id": 32655,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs increase bleeding when given to a patient on warfarin except?</span></span></span></p>",
      "unique_key": "Q5202963",
      "question_audio": null,
      "question_video": null,
      "map_id": 36292,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Carbamazepine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Carbamazepine</strong> is an<strong> enzyme inducer and increases the metabolism of warfarin</strong>. This will<strong> reduce the action of warfarin,</strong> <strong>decreasing</strong> the <strong>risk of bleeding.</strong> <strong>All other drugs</strong> given in the options<strong> increase the risk of bleeding with warfarin</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Isoniazid:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Isoniazid is an<strong> inhibitor of CYP2C9</strong>, which can<strong> inhibit the metabolism of warfarin.</strong> This<strong> inhibition leads to</strong> <strong>increased plasma concentration of warfarin</strong>, thereby <strong>increasing the risk of bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiodarone is also an<strong> inhibitor of CYP2C9.</strong> Like isoniazid, it<strong> inhibits the metabolism of warfarin,</strong> leading to <strong>increased plasma concentration</strong> and an<strong> increased risk of bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Cimetidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Cimetidine</strong> is yet another<strong> inhibitor of CYP2C9.</strong> As with<strong> isoniazid and amiodarone, </strong>it<strong> inhibits the metabolism</strong> of<strong> warfarin,</strong> resulting in<strong> elevated plasma concentrations</strong> and an<strong> increased </strong>likelihood of<strong> bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Carbamazepine, </strong>as an<strong> enzyme inducer, decreases</strong> the <strong>plasma concentration of warfarin, reducing </strong>the <strong>risk of bleeding</strong> when<strong> used</strong> <strong>concomitantly.</strong></span></span><strong> </strong></span></span></span></p>",
      "correct_choice_id": 32654,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8228,
      "choices": [
        {
          "id": 32879,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban</span></span></span></p>"
        },
        {
          "id": 32880,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Argatroban</span></span></span></p>"
        },
        {
          "id": 32881,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
        },
        {
          "id": 32882,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bivalirudin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is orally active direct Xa inhibitor? </span></span></span></p>",
      "unique_key": "Q8061906",
      "question_audio": null,
      "question_video": null,
      "map_id": 36291,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Rivaroxaban</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Rivaroxaban</strong> is an<strong> orally active direct Factor Xa inhibitor.</strong> It works by<strong> selectively inhibiting Factor Xa,</strong> an important enzyme in the <strong>coagulation cascade </strong>that<strong> leads to the formation of thrombin</strong> and <strong>development of a clot.</strong> By <strong>inhibiting Factor Xa</strong>,<strong> rivaroxaban</strong> <strong>reduces</strong> the <strong>generation of thrombin and the subsequent formation of blood clots</strong>. It is used for the <strong>prevention and treatment</strong> of various<strong> thromboembolic disorders</strong>, including<strong> deep vein thrombosis (DVT), pulmonary embolism (PE), and</strong> <strong>stroke prevention</strong> in patients with <strong>non-valvular atrial fibrillation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option B. Argatroban</strong>: Argatroban is a<strong> direct thrombin inhibitor,</strong> not a Factor Xa inhibitor. It is administered<strong> intravenously </strong>and is <strong>used </strong>primarily in patients with <strong>heparin-induced thrombocytopenia (HIT).</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option C. Dabigatran:</strong> <strong>Dabigatran</strong> is also a<strong> direct thrombin inhibitor</strong> but <strong>differs from argatroban</strong> in that it is<strong> orally active</strong>. It is <strong>not</strong> a <strong>Factor Xa inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D. Bivalirudin:</strong> <strong>Bivalirudin</strong> is <strong>another direct thrombin inhibitor,</strong> used <strong>intravenously, </strong>particularly in patients undergoing <strong>percutaneous coronary intervention (PCI). </strong>It is<strong> not </strong>a<strong> Factor Xa inhibitor</strong> and <strong>not orally active.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to recognize the<strong> classification of anticoagulant drugs</strong>, specifically identifying <strong>rivaroxaban </strong>as an <strong>orally active direct Factor Xa inhibitor. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Classification of Anticoagulants</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture8.jpg\" style=\"height:466px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 32879,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8108,
      "choices": [
        {
          "id": 32400,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is a bleeding disorder caused by a deficiency of von Willebrand factor (vWF) </span></span></span></p>"
        },
        {
          "id": 32401,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is a rare condition that only occurs in patients with a history of thrombosis</span></span></span></p>"
        },
        {
          "id": 32402,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is caused by the formation of antibodies against platelet factor 4 (PF4) complexed with heparin.</span></span></span></p>"
        },
        {
          "id": 32403,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is characterized by a normal platelet count and increased risk of bleeding.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is correct about heparin-induced thrombocytopenia (HIT)?</span></span></span></p>",
      "unique_key": "Q5755001",
      "question_audio": null,
      "question_video": null,
      "map_id": 36293,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. HIT is caused by the formation of antibodies against platelet factor 4 (PF4) complexed with heparin.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Heparin-induced thrombocytopenia (HIT) </strong>is an<strong> immune-mediated adverse effect</strong> of<strong> heparin therapy. </strong>It occurs when the<strong> immune</strong> <strong>system </strong>forms<strong> antibodies against a complex of heparin and platelet factor 4 (PF4).</strong> This immune reaction can<strong> activate platelets,</strong> leading to <strong>thrombocytopenia and an increased risk of thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong>. <strong>HIT</strong> is<strong> not</strong> related to<strong> von Willebrand factor (vWF)</strong>; <strong>vWF deficiency</strong> causes<strong> von Willebrand disease,</strong> a <strong>different</strong> <strong>bleeding disorder.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>. <strong>HIT</strong> can occur in any<strong> patient receiving heparin, not </strong>just those with a <strong>history of thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>. <strong>HIT</strong> is characterized by a<strong> decreased platelet count (thrombocytopenia)</strong>,<strong> not</strong> a<strong> normal count, </strong>and it is associated with an<strong> increased risk of thrombosis, not bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Heparin-induced thrombocytopenia (HIT)</strong> is a <strong>serious </strong>and potentially<strong> life-threatening condition </strong>characterized by the<strong> formation of</strong> <strong>antibodies </strong>to complexes formed between<strong> heparin and PF4,</strong> leading to <strong>platelet activation and an increased risk of thrombosis</strong> despite a<strong> decrease in platelet count</strong>. Management involves <strong>discontinuation of heparin and initiation of alternative anticoagulation </strong>with agents like<strong> direct thrombin inhibitors.</strong></span></span></span></p>",
      "correct_choice_id": 32402,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8250,
      "choices": [
        {
          "id": 32967,
          "text": "<p><span style=\"font-size:12pt;\">Act through inhibition of coagulation factor VIII</span></p>"
        },
        {
          "id": 32968,
          "text": "<p><span style=\"font-size:12pt;\">Protamine sulphate reverses its action.</span></p>"
        },
        {
          "id": 32969,
          "text": "<p><span style=\"font-size:12pt;\">Monitoring is done through INR.</span></p>"
        },
        {
          "id": 32970,
          "text": "<p><span style=\"font-size:12pt;\">Target INR for patients of Pulmonary embolism on warfarin therapy is generally 6-8</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Which of the following statements is true about warfarin?</span></p>",
      "unique_key": "Q1676174",
      "question_audio": null,
      "question_video": null,
      "map_id": 36297,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. C. Monitoring is done through INR.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Warfarin</strong> is an <strong>oral anticoagulant</strong> that acts by<strong> inhibiting the activation of vitamin K-dependent clotting factors II, VII, IX, and X </strong>in the <strong>liver.</strong> It is used to prevent and treat thromboembolic disorders, such as<strong> deep vein thrombosis</strong>, <strong>pulmonary embolism</strong>, <strong>atrial</strong> <strong>fibrillation</strong>, and<strong> mechanical heart valves</strong>. The<strong> therapeutic effect of warfarin </strong>is <strong>monitored</strong> by the<strong> International Normalized Ratio</strong> <strong>(INR)</strong>, which is a<strong> standardized</strong> measure of the patient's<strong> prothrombin time (PT) </strong>compared to a <strong>normal control.</strong> The <strong>target INR </strong>range <strong>depends on the indication</strong> and the patient's <strong>individual risk of bleeding and thrombosis</strong>, but it is typically <strong>2.0-3.0</strong> for most indications.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;<strong>Act through inhibition of coagulation factor VIII:</strong> <strong>Warfarin</strong> primarily<strong> inhibits the synthesis of vitamin K-dependent clotting</strong> <strong>factors II, VII, IX, and X in the liver</strong>. It <strong>does not</strong> specifically target<strong> factor VIII.</strong> Therefore, this statement is <strong>incorrect.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Protamine sulphate reverses its action:</strong> <strong>Protamine sulfate</strong> is a <strong>specific antidote</strong> for<strong> heparin, not warfarin.</strong> Warfarin's anticoagulant effect can be<strong> reversed with vitamin K </strong>or <strong>prothrombin complex concentrate</strong>s. Therefore, this statement is<strong> incorrect.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Target INR for patients of Pulmonary embolism on warfarin therapy is generally 6-8:&nbsp;</strong>The <strong>target INR </strong>range for patients on <strong>warfarin therapy </strong>depends on the <strong>indication,</strong> but a <strong>target INR of 6-8 is excessively high</strong> and associated with an <strong>increased risk of</strong> <strong>bleeding</strong>. For most indications, including<strong> pulmonary embolism,</strong> the <strong>target INR range</strong> is typically<strong> 2.0-3.0. </strong>Therefore, this statement is <strong>incorrect.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"color:black;font-size:12.0pt;\"><strong>Monitoring of warfarin therapy </strong>is done through the<strong> International Normalized Ratio (INR), </strong>which is a<strong> standardized </strong>measure of the patient's<strong> prothrombin time (PT) </strong>compared to a <strong>normal control.</strong></span></p>",
      "correct_choice_id": 32969,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8271,
      "choices": [
        {
          "id": 33051,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idarucizumab- dabigatran</span></span></span></p>"
        },
        {
          "id": 33052,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Andexanet alfa- rivaroxaban</span></span></span></p>"
        },
        {
          "id": 33053,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ciraparantag- fondaparinux</span></span></span></p>"
        },
        {
          "id": 33054,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Andexanet- apixaban</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following anticoagulant and its FDA approved antidote is not correctly matched?</span></span></p>",
      "unique_key": "Q5188570",
      "question_audio": null,
      "question_video": null,
      "map_id": 36295,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Ciraparantag- fondaparinux</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ciraparantag (also known as aripazine)</strong> is an investigational drug being studied as a <strong>universal reversal agent</strong> for the <strong>anticoagulant</strong> effects of<strong> various anticoagulants</strong>, including <strong>heparins and direct oral anticoagulants (DOACs)</strong>. However, it <strong>has not</strong> been approved for clinical use till now, and therefore, it is<strong> not currently</strong> an established<strong> antidote for fondaparinux </strong>or any <strong>other anticoagulant.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Idarucizumab- dabigatran:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Idarucizumab is a<strong> monoclonal antibody</strong> that is the approved <strong>antidote for dabigatran</strong>. It <strong>reverses the anticoagulant</strong> effect of <strong>dabigatran</strong> by <strong>binding to it</strong> with <strong>high affinity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Andexanet alfa- rivaroxaban:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Andexanet alfa</strong> is a <strong>recombinant modified </strong>human factor<strong> Xa decoy protein</strong> that <strong>acts</strong> as an <strong>antidote to factor Xa inhibitors,</strong> including <strong>rivaroxaban.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Andexanet- apixaban:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Andexanet alfa</strong> is also the approved <strong>antidote for apixaban,</strong> reversing <strong>its anticoagulant effect</strong> by acting as a <strong>decoy for the drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to know the<strong> specific antidotes for various anticoagulants </strong>and to be aware of the <strong>correct pairing</strong> <strong>between</strong> <strong>these antidotes</strong> and their <strong>corresponding drugs. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antidotes for anticoagulants (DOAC)</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture15.jpg\" style=\"height:515px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 33053,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8083,
      "choices": [
        {
          "id": 32300,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ticlopidine</span></span></span></p>"
        },
        {
          "id": 32301,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ticagrelor</span></span></span></p>"
        },
        {
          "id": 32302,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clopidogrel</span></span></span></p>"
        },
        {
          "id": 32303,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prasugrel</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not a prodrug?</span></span></span></p>",
      "unique_key": "Q1588862",
      "question_audio": null,
      "question_video": null,
      "map_id": 36296,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Ticagrelor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ticagrelor</strong> is not a prodrug. It is an <strong>oral antiplatelet agent </strong>that belongs to the class of <strong>cyclopentyltriazolopyrimidines</strong>. Unlike <strong>prodrugs,</strong> which require<strong> metabolic activation </strong>to become <strong>pharmacologically active</strong>, <strong>ticagrelor </strong>is <strong>active</strong> in its<strong> administered form</strong>. It exerts its<strong> antiplatelet effect </strong>by<strong> directly and reversibly binding to the P2Y12 class of ADP receptors on platelets</strong>,<strong> inhibiting platelet</strong> <strong>activation and aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Ticlopidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ticlopidine is a<strong> thienopyridine antiplatelet agent</strong>, <strong>similar</strong> to<strong> clopidogrel and prasugrel, </strong>and is a prodrug. It requires<strong> metabolic activation</strong> by the<strong> liver </strong>to form its <strong>active metabolite</strong>, which then <strong>inhibits the P2Y12 adenosine diphosphate (ADP</strong>) r<strong>eceptor on platelets, preventing platelet activation and aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Clopidogrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clopidogrel is another<strong> thienopyridine</strong> class<strong> antiplatelet medication</strong> and a <strong>prodrug. </strong>It requires<strong> hepatic</strong> <strong>biotransformation</strong> to an <strong>active metabolite </strong>that<strong> inhibits the P2Y12 component of ADP receptors on the surface of platelets</strong>, <strong>reducing platelet aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Prasugrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prasugrel is also a<strong> thienopyridine antiplatelet drug </strong>and a <strong>prodrug</strong>. It is<strong> rapidly metabolized</strong> to <strong>its active</strong> <strong>metabolite </strong>in the body, which then <strong>irreversibly binds</strong> to the <strong>P2Y12 receptor on platelets,</strong> <strong>inhibiting platelet activation </strong>and <strong>aggregation</strong> <strong>more efficiently</strong> and consistently than<strong> clopidogrel.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to <strong>identify the antiplatelet agent</strong> that is<strong> not a prodrug </strong>among the options provided. Understanding the <strong>distinction </strong>between <strong>prodrugs and drugs</strong> that are <strong>active in their administered form </strong>is crucial for <strong>pharmacological knowledge,</strong> especially in the context of antiplatelet therapy<strong>. Prodrugs </strong>require<strong> metabolic activation </strong>to exert their <strong>pharmacological effects,</strong> whereas drugs like<strong> ticagrelor are active upon administration,</strong> offering a <strong>different profile of onset, duration, and potentially side</strong> <strong>effect profiles,</strong> which can impact<strong> clinical decisions</strong> in the management of<strong> cardiovascular diseases.</strong></span></span></span></p>",
      "correct_choice_id": 32301,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8110,
      "choices": [
        {
          "id": 32408,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral iron should be given until haematocrit normalizes and then discontinued due to gastric adverse effects.</span></span></span></p>"
        },
        {
          "id": 32409,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Before administering parenteral iron, the dose should be diluted and checked for anaphylaxis.</span></span></span></p>"
        },
        {
          "id": 32410,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is 50% absorption from 325 mg of ferrous sulfate via oral route.</span></span></span></p>"
        },
        {
          "id": 32411,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parenteral iron is the preferred treatment due to adverse effects of oral iron.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is true regarding iron replacement therapy for iron deficiency anaemia?</span></span></span></p>",
      "unique_key": "Q1787905",
      "question_audio": null,
      "question_video": null,
      "map_id": 36294,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Before administering parenteral iron, the dose should be diluted and checked for anaphylaxis.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Parenteral iron</strong> therapy requires a test <strong>dose to monitor </strong>for potential<strong> allergic reactions</strong>, including<strong> anaphylaxis.</strong> It is a <strong>crucial safety</strong> measure given the <strong>risk</strong> of <strong>severe hypersensitivity reactions.</strong> This therapy is usually considered when <strong>oral iron is not tolerated,</strong> is <strong>ineffective,</strong> or if there is a need for<strong> rapid repletion of iron stores.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Oral iron</strong> therapy typically <strong>continues until hemoglobin and hematocrit are normalized </strong>and should proceed for <strong>several</strong> <strong>months afterward </strong>to <strong>replenish iron stores.</strong> <strong>Discontinuation </strong>solely due to <strong>gastric side effects</strong> is <strong>not routine practice.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Absorption of oral ferrous sulfate</strong> is <strong>not</strong> as high as <strong>50%; </strong>it is<strong> usually </strong>around <strong>10-20%, </strong>and it is influenced by various factors like <strong>dietary components and patient&rsquo;s iron status.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Oral iron</strong> is the preferred <strong>initial treatment for iron deficiency anemia</strong> due to <strong>convenience, cost-effectiveness</strong>, and generally<strong> good tolerability. Parenteral iron</strong> is <strong>reserved</strong> for <strong>specific circumstances.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When using <strong>parenteral iron</strong> for <strong>iron deficiency anemia,</strong> a <strong>test </strong>dose is necessary to <strong>monitor for anaphylaxis</strong>. <strong>Oral iron </strong>remains the <strong>first-line treatment</strong>, with <strong>continuation after normalization of hematocrit </strong>to<strong> replenish iron stores</strong>, while<strong> parenteral iron</strong> is used <strong>under specific conditions.</strong></span></span></span></p>",
      "correct_choice_id": 32409,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8154,
      "choices": [
        {
          "id": 32584,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prasugrel</span></span></span></p>"
        },
        {
          "id": 32585,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abciximab</span></span></span></p>"
        },
        {
          "id": 32586,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tirofiban</span></span></span></p>"
        },
        {
          "id": 32587,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Eptifibatide</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are Gp IIb/IIIa inhibitors except:</span></span></span></p>",
      "unique_key": "Q7585198",
      "question_audio": null,
      "question_video": null,
      "map_id": 36290,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Prasugrel</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prasugrel</strong> is <strong>not a glycoprotein (Gp) IIb/IIIa inhibitor.</strong> It is a<strong> thienopyridine</strong> <strong>class antiplatelet agent, </strong>similar to <strong>clopidogrel,</strong> that works by <strong>irreversibly inhibiting the P2Y12 subtype of ADP receptor on platelets, </strong>thus <strong>preventing platelet activation </strong>and<strong> aggregation.</strong> <strong>Prasugrel</strong> is a <strong>prodrug</strong> that requires<strong> metabolic activation in the liver.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Abciximab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Abciximab is a<strong> Gp IIb/IIIa inhibitor.</strong> It is a <strong>monoclonal antibody</strong> that <strong>binds</strong> to the <strong>Gp IIb/IIIa receptor </strong>on <strong>platelets</strong>, <strong>preventing the binding of fibrinogen</strong> and <strong>von Willebrand factor</strong>, which <strong>inhibits platelet aggregation.</strong> It is <strong>used</strong> in <strong>acute</strong> <strong>coronary syndrome</strong> and during <strong>percutaneous coronary interventions</strong> to <strong>prevent thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tirofiban:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tirofiban is a<strong> non-peptide antagonist of the Gp IIb/IIIa receptor, </strong>which <strong>inhibits platelet aggregation</strong> by <strong>preventing fibrinogen binding to the Gp IIb/IIIa receptor.</strong> It is used to<strong> prevent thrombotic cardiovascular events</strong> in patients with <strong>acute coronary syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Eptifibatide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Eptifibatide is a <strong>cyclic heptapeptide and a Gp IIb/IIIa inhibitor</strong>. It works by<strong> reversibly blocking the Gp IIb/IIIa receptor</strong>, thereby <strong>inhibiting platelet aggregation. </strong>It is <strong>used </strong>in the management of<strong> acute coronary syndrome </strong>and during <strong>percutaneous coronary interventions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to <strong>recognize the classification of antiplatelet agents</strong>, particularly <strong>distinguishing between Gp IIb/IIIa inhibitors (abciximab, tirofiban, and eptifibatide) </strong>and <strong>other classes of antiplatelet drugs </strong>such as <strong>prasugrel, </strong>which <strong>acts on</strong> the <strong>P2Y12 ADP receptor</strong>, not the Gp IIb/IIIa receptor. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ANTIPLATELET DRUGS</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture5.jpg\" style=\"height:474px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 32584,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}